Dolocodon 5 mg prolonged-release tablets Dolocodon 10 mg prolonged-release omeprazole tablets Doloc

Medications "a" medicinal product "b" Medications "c" Medications "d" Medications "e" Medications "f" Medications "g" omeprazole Medications "h" Medications "i" Medications "j" Medications "k" Medications omeprazole "l" Medications " m 'Drugs' n 'Drugs' o 'Medication' p 'Drugs' R 'Medication' s "Medications" z "Drugs" T "Medications" u "Medications" V "Medications" W "Drugs" omeprazole q "Medications" x " Medications 'Y'
Dolocodon 5 mg prolonged-release tablets Dolocodon 10 mg prolonged-release omeprazole tablets Dolocodon omeprazole 20 mg prolonged-release tablets Dolocodon 40 mg prolonged-release tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION omeprazole
Dolocodon 5 mg: Each prolonged-release tablet contains 5 mg of oxycodone hydrochloride equivalent to 4.5 mg of oxycodone. Dolocodon 10 mg: Each prolonged-release tablet contains 10 mg of oxycodone hydrochloride equivalent to 9 mg of oxycodone. Dolocodon 20 mg: Each prolonged-release tablet contains 20 mg of oxycodone hydrochloride equivalent to 17.9 mg of oxycodone. Dolocodon 40 mg: Each prolonged-release tablet contains 40 mg of oxycodone hydrochloride equivalent to 36 mg of oxycodone. omeprazole INN. Oxycodonum 3 PHARMACEUTICAL FORM
Prolonged-release tablet. Dolocodon 5 mg: white to off-white, round, biconvex film-coated tablets. Dolocodon 10 mg tablets: Pink, oblong, biconvex, film-coated tablets, scored on both sides. The tablet can be divided into equal halves. Dolocodon 20 mg: white to off-white, oblong, biconvex, film-coated tablets, scored on both sides. The tablet can be divided into equal halves. Dolocodon 40 mg tablets: Pink, oblong, biconvex, film-coated tablets, scored on both sides. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS omeprazole 4.1 Therapeutic
Doses are determined depending on the severity of the pain, the patient's individual susceptibility to treatment. Featured in the following general dosing regimens: Adults and adolescents (> 12 years), dose titration and adjustment of the general opioid naïve patients, a starting dose of 10 mg of oxycodone hydrochloride administered at 12 hour intervals. Some patsientiel may also help the starting dose of 5 mg to minimize adverse effects. omeprazole Already receiving opioids for patients start treatment at higher doses, given their previous opioid experience. On the basis of well-controlled clinical trials, has 10 .. 13 mg oxycodone oral dosage equivalent to a dose of approximately 20 mg of morphine, when both of the prolonged-release formulation. Due to differences in the individual sensitivity of various opioids, it is advisable to start a patient Dolocodon prolonged release tablets at the transition to other opioids fairly conservatively, estimated as 50 to 75% .. the calculated dose of oxycodone. Some patients who take Dolocodon prolonged-release omeprazole tablets at regular intervals, may be in need of an immediate-release formulation than the so-called emergency alangeetikumi breakthrough pain coupe for the position. Dolocodon prolonged-release tablets are not intended for the treatment of acute pain and / or breakthrough omeprazole pain. Emergency Painkiller single dose should be 1/6 Dolocodon prolonged-release tablets omeprazole ekvialanalgeetilisest daily dose of the object. If the so-called emergency medication must be administered more than twice a day, it refers to the need to increase Dolocodon prolonged-release tablets in doses. The dosage should not increase more than once every 1 .. 2 days, until a stable twice-daily administration. After increasing the dose to 10 mg to 20 mg every 12 hours, the doses may be hereinafter referred to adjust gradually for about one third per daily dose. The objective is achieved by a patient-specific dosage, which is administered twice daily and provides adequate analgesia with tolerable side effects in order to minimize the need for emergency analgesic agent, may be needed because of the long-term omeprazole treatment. Equal distribution (of the same dose in the morning and evening) after the use of a fixed dose regimen (every 12 hours) has been shown to be suitable for the majority of patients. For some patients, it is beneficial to equally omeprazole distribute doses. The general rule is to choose the lowest effective analgesic dose of non-malignant tumor-induced pain, the daily dose of 40 mg were generally sufficient, but may require a larger omeprazole dosage. Patients with pain due to cancer omeprazole may require up to 80 .. 120 mg, which may increase in individual cases up to 400 mg. If needed, even higher doses,